Teva Pharma Trims FY22 Revenue Outlook - Update

While reporting financial results for the first quarter on Tuesday, Teva Pharmaceutical Industries Ltd (TEVA) trimmed its revenue guidance for the full-year 2022 to reflect ongoing impact of foreign exchange fluctuations.

For fiscal 2022, the company still projects adjusted earnings in a range of $2.40 to $2.60 per share on adjusted revenues now expected between $15.4 billion and $16.0 billion, down from the prior guidance range of $15.6 billion to $16.2 billion.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $2.51 per share on revenues of $15.97 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is looking to set a new framework to further improve and maintain the supply of infant formula to ensure that American consumers have access to safe and nutritious infant formula. Infant formula is an essential food product that is the sole source of nutrition for many babies in the U.S. Amazon has unveiled millions of deals worldwide that will be available during its upcoming Prime Day extravaganza. The 48-hour shopping event for Prime members kicks off July 12 at 3 a.m. EDT, offering deals of up to 79% off across various categories. These include electronics, devices, toys, beauty, fashion, and home, from top national brands and small businesses. Primal Pet Foods is recalling a single lot of Raw Frozen Primal Patties for Dogs Beef Formula due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves lot #W10068709 of 6-pound Raw Frozen Primal Patties with best by date of 05/22/23. The Raw Frozen Primal Patties are sold in flexible packaging in the freezer at select pet stores.
Follow RTT